Entrada (Fringe)

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent business updates.

Key Points: 
  • We are well positioned to execute on our strategic initiatives to create value for patients and shareholders alike, said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Entrada expects to file its first Investigational New Drug (IND) application for ENTR-601-44 for patients with Duchenne who are amenable to exon 44 skipping in the fourth quarter of 2022.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2022 were $19.0 million, compared to $10.5 million for the same period in 2021.
  • Net Loss: Net loss for the third quarter of 2022 was $25.1 million, compared to $14.4 million for the same period of 2021.

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent business updates.

Key Points: 
  • We continued to make significant progress in advancing our growing pipeline of EEV therapeutic candidates during the second quarter, said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2022 were $16.2 million, compared to $6.8 million for the same period in 2021.
  • General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2022 were $7.3 million, compared to $3.1 million for the same period in 2021.
  • Net Loss: Net loss for the second quarter of 2022 was $23.2 million, compared to $9.9 million for the same period of 2021.